Grace Therapeutics (GRCE) Non-Current Deferred Tax Liability (2022 - 2026)

Grace Therapeutics has disclosed Non-Current Deferred Tax Liability across 5 years of filings, most recently posting $612000.0 for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability fell 73.53% year-over-year to $612000.0; the TTM figure through Jun 2026 stood at $612000.0 (down 73.53% YoY), while the FY2026 annual figure was $612000.0, down 73.53% from the prior year.
• Non-Current Deferred Tax Liability came in at $612000.0 for Q2 2026 at Grace Therapeutics, roughly flat from $612000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $16.9 million in Q1 2022 to a low of $612000.0 in Q1 2026.
• Average Non-Current Deferred Tax Liability over 5 years is $7.4 million, with a median of $5.6 million recorded in 2023.
• Year-over-year, Non-Current Deferred Tax Liability fell 6.8% in 2024 and slumped 79.66% in 2025.
• Over 5 years, Non-Current Deferred Tax Liability stood at $16.2 million in 2022, then tumbled by 60.52% to $6.4 million in 2023, then plunged by 47.95% to $3.3 million in 2024, then sank by 30.63% to $2.3 million in 2025, then tumbled by 73.53% to $612000.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $612000.0 in Q2 2026, $612000.0 in Q1 2026, and $2.3 million in Q4 2025.